Melanoma Clinical Trials in New York

Showing 121-140 of 172 trials

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

NCT01673854

The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.

Melanoma

Bristol-Myers Squibb70 participantsStarted Sep 2012

Beverly Hills, California, United States • Jacksonville, Florida, United States • Orlando, Florida, United States +11 more locations

TERMINATEDPHASE2< 1 mile

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

NCT01689974

An attractive area of research regards immune manipulations to recover some of the patient's immune response to his/her tumor, a strategy that has the advantages of being both natural and potentially long-lasting.\[1\] We propose to combine immunotherapy with radiotherapy directed to a metastatic site, to create a "hub" for in vivo immunization to the tumor, to enable "tumor rejection" at the other metastatic sites. This "in vivo immunization" is explored as a viable alternative to an individualized vaccine approach. Preclinical data generated by us and others support a "proof of principle" clinical trial that may open the field to an alternative use of radiotherapy in a novel partnership with cancer immunotherapy.\[2\]

Metastatic Melanoma

NYU Langone Health10 participantsStarted Jan 2013

New York, New York, United States

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

Melanoma Trials in Other Cities

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

CCI-779 in Treating Patients With Metastatic Melanoma

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Other Conditions in New York